Peter Attia· MD
what he said was based on all of the evidence he had examined to date of the use of rapamycin even in patients with transplant it's antiproliferative properties alone speak to this and it's so funny to hear you say what you just said because he said the exact same thing he said think about it Peter every chronic disease is some amount of hyper proliferation hyper growth and you have a drug here that in the most elegant way in the least toxic way in the most specific way targets one of the most important regulators of growth